AÉMA-GROUPE
15.6.2021 09:07:07 CEST | Business Wire | Press release
MACIF, Aéma Groupe’s affiliate, announces the successful issuance of a multi-tranche €1.75bn subordinated debt issuance comprising:
- a €400mn Perpetual Non-Call 2029 Restricted Tier 1 fixed resettable rate notes bearing interest at an initial fixed rate of 3.50% until the first call date and expected to be rated Ba1 by Moody’s
- a €850mn 2052 Non-Call 2032 Tier 2 fixed to floating rate notes bearing interest at an initial fixed rate of 2.125% until the first call date and expected to be rated Baa1 by Moody’s
- a €500mn 2027 Tier 3 notes bearing interest at a 0.625% fixed rate coupon and expected to be rated Baa1 by Moody’s
MACIF has met with over 85 institutional investors over phone calls which took place from 8th to 11th June 2021 in order to present the Group’s credit. With more than 400 investors participating into the multi-tranche transaction for a total book size over €12.1bn, this represents the first Euro triple-tranche subordinated from a European insurer.
The three days of virtual roadshow conducted as part of this capital increase have again proved the great appetite of investors towards Macif's solid business model.
These transactions constitute a significant part of Aviva France’s acquisition financing and the proceeds of the notes will be eligible for inclusion in Solvency II regulatory capital, reinforcing the newly formed Group capital base.
Credit Suisse acted as Structuring Advisor and Global Coordinator, HSBC and Natixis acted Global Coordinators and BBVA, BNP Paribas, JP Morgan, ING, RBC and Société Générale acted as Joint Lead Managers on these transactions.
About Aéma Groupe
Aéma Groupe is the mutual protection group resulting from the merger between Aésio and Macif.
With 8 million policy-holders, it employs 14,000 people and has a turnover of 8 billion euros in France.
Every day, Aéma Groupe imagines the outlines of a fairer and more humane world by placing thoughtfulness at the heart of its relationship with its members, shareholders and corporate clients..
Find out more : aemagroupe.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005506/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Beast Industries Acquires Step, Expanding its Platform to Include Financial Services9.2.2026 18:30:00 CET | Press release
This strategic acquisition brings innovative fintech capabilities to Beast Industries’ growing global platform, combining technology, content, and purpose to redefine financial services for the next generation Beast Industries, the largest and most innovative creator based platform in the world, today announced the acquisition of Step, a financial technology company dedicated to making financial literacy and money management accessible to all. This acquisition marks a significant milestone for Beast Industries, bringing together Step's robust technology platform and full-stack fintech team with Beast Industries’ extensive audience reach and proven track record in philanthropic initiatives. Together, the combined organization will deliver innovative solutions that make financial wellness achievable for people at every step of their life journey. "Financial health is fundamental to overall wellbeing, yet too many people lack access to the tools and knowledge they need to build financial
Align Partners Issues Public Shareholder Letter and Submits Formal Shareholder Proposals to DB Insurance9.2.2026 15:26:00 CET | Press release
Align Partners underscores DBI’s persistent undervaluation (0.40x Adjusted PBR), despite industry-leading profitability, identifying inefficient capital allocation and governance issues as primary driversAlign Partners outlines measures for capital efficiency and governance normalization; requests a revised “Value-up” plan and a formal response from the Board by March 6, 2026The proposals nominate two Independent Directors via separate election and calls for the reinstatement of the Internal Transaction Committee Align Partners Capital Management Inc. (“Align Partners”), a shareholder of DB Insurance Co., Ltd. (KRX:005830) (“DBI” or the “Company”) holding 1.9%, has issued a public shareholder letter to DBI’s Board of Directors aimed at strengthening capital allocation policy and governance oversight, and submitted formal shareholder proposals for the 2026 Annual General Meeting (“AGM”). Despite DBI’s robust fundamentals—including a 16.1% ROE and a 226% K-ICS ratio—the Company trades at
Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 13:00:00 CET | Press release
TarSeer™ BRETSA™ Target Engagement System enables studies for difficult proteins early in drug discovery Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/
Eurofins Viracor BioPharma Expands Bioanalytical Capabilities9.2.2026 13:00:00 CET | Press release
Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built, eleven‑acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins V
HKTDC to Host World’s Largest One-Stop Jewellery Marketplace9.2.2026 11:37:00 CET | Press release
New Hard Pure Gold Pavilion showcases breakthrough gold technologies Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one‑stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld‑Expo, featuring a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre, showcasing finished jewellery pieces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207153040/en/ Hong Kong International Jewellery Show and Hong Kong International Diamond, Gem & Pearl Show Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with nearly 70% coming
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
